These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Synthesis and antitumor properties of rubomycin 13-cyclohexylidene hydrazone].
    Author: Tarasova VE, Ul'ianova LA, Povarov LS, Odnoralets EN.
    Journal: Antibiot Med Biotekhnol; 1987 Jan; 32(1):27-31. PubMed ID: 3566226.
    Abstract:
    Rubomycin 13-cyclohexylidene hydrazone (RCH) was synthesized by interaction of rubomycin 13-hydrazone with cyclohexane. Antitumor activity of RCH was studied in comparison to that of the initial rubomycin on mice with ascitic lymphadenosis NK/Ly, Ehrlich carcinoma, hemocytoblastosis La, leukemia P-388, solid lymphosarcoma LIO-1 and sarcoma 180. It was shown that RCH was actually equal to rubomycin by its selective activity against lymphadenosis NK/Ly and sarcoma 180 on its 4- and 2-fold intravenous administration, respectively. RCH was superior to rubomycin by its selective activity against lymphosarcoma LIO-1 and Ehrlich carcinoma and was more efficient in treatment of hemocytoblastosis La. RCH was inferior to rubomycin by its efficacy in treatment of lymphadenosis NK/Ly on its 2-fold oral administration and against leukemia P-388 on its 2-fold intravenous administration. Comparison of RCH with an analogous derivative of carminomycin showed that analogous changes in the chemical structure of rubomycin and carminomycin induced different changes in the chemotherapeutic properties of the initial substances.
    [Abstract] [Full Text] [Related] [New Search]